Article Text

other Versions

PDF
An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF)
  1. Leah Raj1,
  2. Bhavin Adhyaru2
  1. 1Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  2. 2Division of General Internal Medicine & Geriatrics, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
  1. Correspondence to Dr Leah Raj, Department of Medicine, Emory University School of Medicine, 49 Jesse Hill Jr. Drive, Atlanta, GA 30303, USA; lraj{at}emory.edu

Abstract

An estimated 5.1 million Americans have chronic heart failure and this is expected to increase 25% by 2030. Heart failure is a clinical syndrome that evolves from either functional or structural changes to the ventricles that lead to filling or ejection abnormalities. Thus far, pharmacotherapy has been show to be beneficial in patients only with reduced ejection fraction; however, new therapies have been developed in hopes of reducing the burden of heart failure. In this review, we will discuss current pharmacotherapies recommended in American College of Cardiology/American Heart Association guidelines, the evidence behind these recommendations as well as new and emerging therapies that have been developed.

Statistics from Altmetric.com

Footnotes

  • Contributors LR and BA determined structure and content of the paper, LR wrote the paper, BA aided with editing and revising the paper.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.